Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vertex's Next Steps Closely Watched Following Merck-Roche Deal On Victrelis

Executive Summary

All eyes are on Vertex Pharmaceuticals and whether it will change course and seek a marketing partner following the May 17 announcement that Merck and Roche will co-promote Merck’s newly approved hepatitis C drug Victrelis (boceprevir).

You may also be interested in...



Pharmasset Casts Wide Phase III Net With Interferon-Free, Two-Drug Combo

Phase II ELECTRON study yielded 100% cure rate across all arms, including interferon-sparing and interferon-free regimens.

Vertex Out To Significant Early Lead In HCV Protease Inhibitor Competition With Merck

Most market analysts predicted Vertex's protease inhibitor would be a bigger seller than Merck's, but a greater than 10-to-1 disparity in third-quarter net sales is still eye-opening.

Vertex Out To Significant Early Lead In HCV Protease Inhibitor Competition With Merck

Most market analysts predicted Vertex's protease inhibitor would be a bigger seller than Merck's, but a greater than 10-to-1 disparity in third-quarter net sales is still eye-opening.

Related Content

Topics

UsernamePublicRestriction

Register

PS053431

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel